Baird Initiates Coverage On ResMed With Outperform Rating, Announces Price Target of $280
Baird Initiates Coverage On ResMed With Outperform Rating, Announces Price Target of $280
Baird開始對瑞思邁進行覆蓋，給予表現評級，宣佈目標股價爲280美元
Baird analyst Joe Vruwink initiates coverage on ResMed (NYSE:RMD) with a Outperform rating and announces Price Target of $280.
Baird 分析師Joe Vruwink 股票分析上瑞思邁（紐交所:RMD）， 給予跑贏市場評級並宣佈目標股價爲280美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。